Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | LA |
he had a fever; ache/pain; This non-serious case was reported by a consumer via call center representative and described the occurrence of fever in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 23-JUN-2025, the patient received the 2nd dose of Shingrix (left arm). On 24-JUN-2025, 1 days after receiving Shingrix, the patient experienced fever (Verbatim: he had a fever) and pain (Verbatim: ache/pain). The outcome of the fever and pain were not resolved. It was unknown if the reporter considered the fever and pain to be related to Shingrix. It was unknown if the company considered the fever and pain to be related to Shingrix. Additional Information: GSK receipt date: 24-JUN-2025 The patient reported that he had received Shingrix vaccine and had a fever (grade/temp not disclosed,) pain and aches. The reporter mentioned that at the time of the call to GlaxoSmithKline, the adverse events had not resolved. No further information was obtained/provided.